Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — Shareholder Meeting (October 2025)
30 slides from Arovella Therapeutics's shareholder meeting presentation, Oct 30, 2025
Slide 1: Interim Chair's Address and CEO Presentation to Annual General Meeting
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX Release 30 October 2025 INTERIM CHAIR’S ADDRESS AND CEO PRESENTATION TO ANNUAL GENERAL MEETING MELBOURNE, AUSTRALIA 30 October 2025: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Ki
Slide 2: Notes to Editors: About Arovella Therapeutics
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 NOTES TO EDITORS: About Arovella Therapeutics Ltd Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cance
Slide 3: Interim Chair's Address
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 Interim Chair’s Address The order of events for today’s Meeting will be as follows: • I will firstly provide an overview of Arovella’s performance during the 2025 financial year (FY25) • We will then hear from the CEO and Managing Director, Dr M
Slide 4: Interim Chair's Address (continued)
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 Let me reiterate the importance of the IND. An accepted IND represents a significant advancement of Arovella’s CAR-iNKT cell platform beyond the ability to commence the phase 1 clinical trial for ALA-101. The IND for ALA-101 will serve as the bl
Slide 5: Annual General Meeting October 2025
ASX:ALA For personal use only Annual General Meeting October 2025
Slide 6: Arovella's Board of Directors
Arovella’s Board of Directors Dr. Liz Stoner Dr. Michael Baker INTERIM CHAIR CEO & MANAGING DIRECTOR For personal use only Dr. Stoner is a distinguished biopharma executive, who brings Dr Baker has over 20 years of experience in scientific decades of international industry experience to her role, re
Slide 7: Interim non-Executive Chair Address
For personal use only Interim non-Executive Chair Address Dr Elizabeth Stoner
Slide 8: CEO and MD Address
For personal use only CEO and MD Address Dr Michael Baker 4
Slide 9: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment advice. 4. Whilst this presentation is based on information from sources which are considered The presentation is not intended to be comprehensive or provide all information reliable, no representation or warr
Slide 10: Key achievements for FY 2025
Key achievements for FY 2025 FY 2025 was a transformative year for Arovella and its proprietary iNKT cell platform For personal use only Completed key manufacturing Completed regulatory steps Continued to enhance the activities for ALA-101 in and initiated clinical readiness CAR-iNKT cell platform p
Slide 11: Financial overview
Financial overview Financial Snapshot ASX CODE ALA ALA Price and Volume - 12 Months1 For personal use only Market capitalisation1 $113.72 million 40,000,000 Shares on issue 1,197.0 million $0.18 52-week low / high $0.068 / $0.210 30,000,000 Cash Balance (30 Sep, 2025) $21.9 million $0.12 Major Share
Slide 12: Recent cell therapy transactions
Recent cell therapy transactions1 Upfront Milestones Total deal Date Type of deal Acquirer/Licensee Target/Licensor Cell Type Stage (US$M) (US$M) value (US$M) Oct-25 Acquisition In vivo CAR Preclinical $1,500 $0 $1,500 Aug-25 Acquisition In vivo CAR Phase 1 $350 $0 $350 For personal use only Jun-25
Slide 13: A differentiated position
A differentiated position T cell and NK cell sectors are competitive For personal use only T cell iNKT cell NK cell Companies with T cell, NK cell, or iNKT cell therapy programs. ASX:ALA Source: Company analysis based on public information 9
Slide 14: Arovella's path to patient
Arovella’s path to patient TECHNOLOGY PRE-CLINICAL LENTIVIRUS MANUFACTURING PHASE 1 CLINICAL PHASE 2 CLINICAL PRODUCT FDA (IND) ACQUISITION CONFIRMATION MANUFACTURING PLATFORM TRIAL TRIAL For personal use only CD19 CAR-iNKT Early Lymphoma ALA-101 2026 CLDN18.2 CAR-iNKT Gastric cancer and pancreatic
Slide 15: Pathway to US FDA IND
Pathway to US FDA IND Arovella is working to have the highest chance of IND acceptance For personal use only Early interactions with the FDA to discuss the Pre-IND proposed clinical program Meeting ALA-101 (CD19 CAR-iNKT) Generation of data for manufacturing and non- Chemistry, clinical studies. Stu
Slide 16: Interaction with the FDA
Interaction with the FDA Positive Type D meeting held For personal use only During the meeting, FDA provided CAR-iNKT) Arovella elected to hold a (CAR19-iNKT) clear guidance on testing requirements Type D meeting with FDA for the reagent (CD19 to obtain additional ALA-101 ALA-101 Much of the testing
Slide 17: Taking ALA-101 into first-in-human trials
Taking ALA-101 into first-in-human trials ALA is progressing towards its ALA-101-001 phase 1 study First patient dosed with ALA-101 For personal use only Ethics approval for ALA-101-001 study in Australia ALA-101 (CD19 CAR-iNKT) Complete manufacturing of clinical batches of ALA-101 File IND applicat
Slide 18: ALA-101-001: study design
ALA-101-001: study design Part 1 Part 2 Dose escalation Dose expansion For personal use only 4 dose levels Dose level(s) selected from Part 1 13-21 participants expected Up to 22 participants CD19+ lymphoma CD19+ lymphoma and leukaemia ALA-101 (CD19 CAR-iNKT) DL4 Dose TBD based on 500M C
Slide 19: iNKT cells to target solid tumours
iNKT cells to target solid tumours For personal use only Arovella is implementing its strategy to target and kill solid tumours – 90% of newly diagnosed cancer cases1 1. https://www.cancer.gov/types/common-cancers 15
Slide 20: iNKT cells are well placed to tackle solid tumours
iNKT cells are well placed to tackle solid tumours iNKT cells have features that may make them useful for treating solid tumours Naturally target cancer Infiltrate tumours and have For personal use only markers and are prognostic NKG2DL shown promising clinical data for survival CD1d in human solid
Slide 21: New CARs
New CARs Add additional CARs for novel targets Arovella’s manufacturing process can be leveraged for multiple cancer types MANUFACTURING For personal use only Isolate iNKT cells Expand to grow billions of CAR-iNKT cells ALA-105 (CLDN18.2 CAR-iNKT) Collect Healthy Engineer iNKT cells to Vial and free
Slide 22: Introducing Claudin 18.2 (CLDN18.2)
Introducing Claudin 18.2 (CLDN18.2) A promising solid tumour target For personal use only Validated target with first monoclonal antibody ALA-105 (CLDN18.2 CAR-iNKT) approved in Japan and the US in CLDN18.2 overexpression has been 2024 identified in several types of cancers Gastric cancer market alo
Slide 23: Arovella's CLDN18.2-targeting CAR is highly active
Arovella’s CLDN18.2-targeting CAR is highly active The CLDN18.2 CAR derived from SPX-101 mediates potent cytotoxicity in T cells For personal use only The licensed CLDN18.2-specific mAb, SPX-101, was converted to a scFv and formatted as a CAR. ALA-105 (CLDN18.2 CAR-iNKT) The activity of Arovella
Slide 24: Taking ALA-105 to IND filing
Taking ALA-105 to IND filing ALA is progressing nonclinical development of ALA-105 File IND with the FDA or other suitable regulator For personal use only Complete IND-enabling studies ALA-105 (CLDN18.2 CAR-iNKT) Complete Process Development to manufacture ALA-105 Manufacture GMP CLDN18.2 CAR lentiv
Slide 25: Arovella's expanding pipeline
Arovella’s expanding pipeline For personal use only ASX:ALA 21
Slide 26: Chair appointment
Chair appointment A rigorous process was undertaken to identify a world class addition to the ALA Board For personal use only Exceptional candidate identified and selected – negotiating the final details Previously at a high-profile Australian life sciences pharmaceutical company Deep scientif
Slide 27: Upcoming milestones for FY2026
Upcoming milestones for FY2026 Jul Dec Jun 2025 2025 2026 For personal use only • Complete IND-enabling studies and file an IND • Complete manufacturing of clinical batches and application with US FDA for Phase 1 commence phase 1 study and generate initial data ALA-101 • Complete preparatory activit
Slide 28: Summary
Summary Novel allogeneic Lead product progressing to CAR-iNKT cell platform clinical trials For personal use only iNKT cells serve as an excellent platform to ALA-101, a potential treatment for CD19- develop allogeneic, or “off-the-shelf”, cell expressing blood cancers, is being therapies to treat c
Slide 29: Cell therapy deal references
Cell therapy deal references 1. https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Strengthens-and-Diversifies-Cell-Therapy-Portfolio-with-Acquisition-of-Orbital- Therapeutics/default.aspx 2. https://interiusbio.com/press-release/kite-to-acquire-interius-biotherapeutics-to-advan
Slide 30: Q&A
ASX:ALA For personal use only Q&A Dr Michael Baker CEO & Managing Director Email: investor@arovella.com Mobile: +61 403 468 187
Arovella Therapeutics — Shareholder Meeting (October 2025) on 6ix